Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednicarbate

FDA-approved product (ointment, topical), marketed as Dermatop, Dermatop E Emollient, Prednicarbate.

Registered studies
3
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Prednicarbate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Contact dermatitis
  • Crohn's disease
  • Dermatitis herpetiformis
  • Dermatomyositis
  • Eosinophilic pneumonia
  • Epicondylitis
  • Erythema multiforme
  • and 43 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, potent (group iii)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednicarbate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednicarbate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis

    NCT07796854 · start 2026-10-01

    Registered record
    Registry ID
    NCT07796854
    Conditions
    Fungal Skin Infection; Tinea Corporis
    Interventions
    Direct microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2027-08-20
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Skin Infection; Tinea Corporis
    InterventionDirect microscopic KOH examination; Culture:; Antifungal susceptibility testing:; Conventional PCR:
    PhaseNot recorded
    Registry statusNot yet recruiting

  • 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

    NCT03399526 · start 2013-02-11

    Registered record
    Registry ID
    NCT03399526
    Conditions
    Psoriasis
    Interventions
    Mapracorat (ZK 245186, BAY 86-5319); Prednicarbate 0.25% ointment; Clobetasol 0.05% ointment; Calcipotriene 0.005% ointment; Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-11
    Completion
    2013-05-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionMapracorat (ZK 245186, BAY 86-5319); Prednicarbate 0.25% ointment; Clobetasol 0.05% ointment; Calcipotriene 0.005% ointment +1 more
    PhasePhase 1
    Registry statusCompleted

  • Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis

    NCT00148746 · start 2004-05

    Registered record
    Registry ID
    NCT00148746
    Conditions
    Moderate to Severe Atopic Dermatitis
    Interventions
    Pimecrolimus; Tacrolimus; Prednisolone; Ciclosporin A; Dermatop
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-05
    Completion
    2008-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Atopic Dermatitis
    InterventionPimecrolimus; Tacrolimus; Prednisolone; Ciclosporin A +1 more
    PhaseNot applicable
    Registry statusCompleted